Rui Xu

Dr. Rui Xu

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RXRui Xu
Rui Xu
Cao ChenCao Chen
Cao Chen
QSQi Shi
Qi Shi
XDXiaoping Dong
Xiaoping Dong
Creutzfeldt–Jakob disease (CJD) is a rare but devastating neurodegenerative disorder characterized by the pathological misfolding of the cellular prion protein (PrPC) into the pathogenic isoform-scrapie prion protein (PrPSc), ultimately leading to fatal outcomes. Cerebrospinal fluid (CSF) biomarkers play a pivotal role in early diagnosis, longitudinal monitoring, and prognostic assessment, thereby enhancing the clinical management of this challenging disease. This review summarizes the established CSF biomarkers, 14-3-3 protein, tau protein (total tau), phosphorylated tau isoforms, α-synuclein, neurofilament light chain (Nfl), S100B, neuron-specific enolase (NSE), and phosphorylated neurofilament heavy chain (pNFH), highlighting typical sensitivity ranges (14-3-3 ~70–85%; RT-QuIC > 90%) and subtype-dependent performance variation. We further dissect limitations related to assay variability, inter-laboratory cut-off inconsistencies, and reduced specificity in non-prion dementias. Looking ahead, we discuss emerging multi-omics discovery, integration of CSF with blood-based biomarkers and imaging signatures, and AI-enabled diagnostic modeling. We propose a three-tier biomarker framework combining Real-Time Quaking-Induced Conversion (RT-QuIC) as a confirmatory assay, tau/NfL/pNFH as injury-severity indicators, and multi-omics-derived signatures for early detection and prognosis stratification.

Verified
Journal Article
Open access
PDF file
BXBing Xu
Bing Xu
KXKang Xiao
Kang Xiao
RXRui Xu
Rui Xu
TSTongxin Sun
Tongxin Sun
FNFangfan Ning
Fangfan Ning
XDXiaoping Dong
Xiaoping Dong
Prion diseases are fatal neurodegenerative disorders characterized by profound neuronal damage. Despite evidence supporting a neuroprotective role for β-synuclein (β-syn) in neurodegeneration, its potential functions and mechanisms in prion disease have not been elucidated. To investigate the role of β-syn, we systematically analyzed its alterations in the central nervous system of several prion-infected rodent models and cell models. A series of biochemical, cellular, and immunofluorescence assays were conducted to explore the relationship between β-syn and protein kinase B (Akt) signaling and between β-syn and prion protein (PrP), and its neuroprotective role in prion disease. Student’s t-test was used for statistics. At the terminal stage of prion disease, β-syn and Akt exhibited a parallel and remarkable decrease in rodent brains, contrasting with the slight but significant increase observed at early to middle stages. Dual-stained immunofluorescence assays confirmed that β-syn is localized within NeuN-positive neurons. Further structural and functional analyses revealed a high-affinity molecular interaction between β-syn and Akt, with the N-terminal region of β-syn being essential for binding to Akt1. In a cell model of PrP aggregation, β-syn overexpression suppressed cytochrome c-induced apoptosis, which was demonstrated by decreased levels of cleaved caspase-3. Notably, this anti-apoptotic effect was partially abolished upon Akt knockdown, indicating a dependence on Akt signaling. Moreover, colocalization of β-syn and PrP was observed in rodent brains. Consistently, in cellular models of prion infection and PrP aggregation, β-syn overexpression not only reduced PrP levels but also ameliorated its aberrant histological distribution. Our findings demonstrate that the anti-apoptotic activity of β-syn, mediated via Akt signaling, is severely lost during prion infection, thereby suggesting a mechanism of intrinsic neuronal vulnerability and revealing a novel therapeutic strategy.

Verified
Journal Article
Open access
PDF file
RXRui Xu
Rui Xu
Cao ChenCao Chen
Cao Chen
TSTong-Xin Sun
Tong-Xin Sun
JLJu-Zheng Li
Ju-Zheng Li
XZXing-Hao Zhai
Xing-Hao Zhai
XDXiaoping Dong
Xiaoping Dong
Prion diseases (PrDs) are fatal neurodegenerative disorders characterized by the accumulation of misfolded prion protein (PrPSc) and progressive impairment of protein quality-control systems. Lysosomal dysfunction and defective autophagic flux contribute to PrPSc accumulation, but the upstream regulatory mechanisms remain incompletely defined. In this study, we investigated the regulatory role of miR-148a-3p during prion infection. We found that miR-148a-3p expression is markedly increased in ME7- and 139A-infected mouse brains and prion-infected SMB-S15 cells. Dual-luciferase assays confirmed that miR-148a-3p directly targets the PRNP 3′UTR, negatively regulating cellular PrP expression. In prion-infected cells, inhibition of miR-148a-3p reduced proteinase K (PK)-resistant PrP (PrPres), delayed RT-QuIC conversion, and decreased PMCA-amplified PrPres. Through bioinformatic prediction and experimental validation, we identified ATP6AP2, a V-ATPase-associated regulator of lysosomal acidification, as a high-confidence target of miR-148a-3p. ATP6AP2 expression was significantly decreased in sCJD transcriptomic data, scrapie-infected mouse brains, and prion-infected cells. Importantly, inhibition of miR-148a-3p restored ATP6AP2 expression, which improved lysosomal acidification and alleviated impaired autophagic flux. Furthermore, overexpression of ATP6AP2 directly reduced PrPSc accumulation in SMB-S15 cells and diminished prion seeding capacities in RT-QuIC and PMCA assays. These findings identify miR-148a-3p as an upstream regulator of ATP6AP2-dependent lysosomal dysfunction in prion infection. Inhibition of miR-148a-3p may restore lysosomal clearance capacity and reduce PrPSc accumulation, suggesting a potential regulatory strategy for PrDs.